Natco Pharma launches generic Hepatitis C treatment drug 'Velpanat' in Nepal
Indian Pharmaceutical Company Natco Pharma Has Launched A Generic Hepatitis C Treatment Drug In Nepal Under The Brand Name 'Velpanat.'
Indian pharmaceutical company Natco Pharma has launched a generic Hepatitis C treatment drug in Nepal under the brand name 'Velpanat.'
The product is the first generic version of Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination sold by Gilead Sciences Inc under brand name Epclusa.
The Hyderabad-based firm has signed a non-exclusive licensing agreement with Gilead Sciences Inc, to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries.
The drug is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection, Natco said in a regulatory filing.
Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for Ribavirin, it added.
"Natco will market Sofosbuvir 400mg/Velpatasvir 100mg under the brand name Velpanat," it said.
The company has priced the medicine at a maximum retail price of Nepalese Rupee 25,000 for a bottle of 28 tablets in Nepal.
For all the Latest Business News, Companies & Commodities News, Download News Nation Android and iOS Mobile Apps.
More from Business
Take Control Of Your Financial Goals: Apply For A Personal Loan Now
Nihal Dangoria: An Indian Entrepreneur Making a Bright Future For The Real Estate Industry
Data breach incident at Extramarks highlights growing cybersecurity concerns in Indian companies
How is ePayLater empowering retailers across the country
Follow your heart, but don't ignore your mind When it comes to investing